Quantcast

Latest Low-density lipoprotein Stories

2014-04-01 08:28:50

New investigational PCSK9 inhibitor shown to significantly reduce LDL-C among Japanese patients BRIDGEWATER, N.J. and TARRYTOWN, N.Y., April 1, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the first Phase 2 study with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), in Japanese patients met its primary endpoint. The results...

2014-04-01 08:28:03

'Hubs' offer personal health consultations, blood draws and group classes in a modern, stylish environment RICHMOND, Va., April 1, 2014 /PRNewswire/ -- Health Diagnostic Laboratory, Inc. is taking the next step in its mission to detect, prevent and reverse major chronic disease such as heart disease and diabetes with the launch of My HDL Hub health centers. HDL, Inc.'s My HDL Hub is a place for individuals to receive comprehensive blood tests, gain lifestyle, nutrition and fitness...

2014-03-31 13:27:54

Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death, heart attack or stroke among patients with type 2 diabetes and recent heart attack or unstable angina, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. Cardiovascular disease remains the dominant cause of death among patients with...

2014-03-31 12:28:19

Findings Presented at the American College of Cardiology Annual Meeting Using the VAP® Lipid Panel Highlight Connection between Lipoproteins and Risk of Coronary Heart Disease WASHINGTON, March 31, 2014 /PRNewswire/ -- Data presented from two meta-analyses using the Atherotech Vertical Auto Profile (VAP(®))( )Lipid Panel showed the impact high-density lipoprotein (HDL) cholesterol and remnant lipoprotein (RLP) cholesterol have on determining a patient's risk for hard coronary heart...

2014-03-31 12:28:14

Data demonstrates that the NMR LipoProfile® test provides clinically reliable information to help reduce cardiovascular events, especially in patients with diabetes and those on statin therapy WASHINGTON, March 31, 2014 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized nuclear magnetic resonance (NMR) diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced data showing that...

2014-03-31 12:28:11

- Reductions of up to 64 percent in triglycerides achieved CARLSBAD, Calif., March 31, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the final results from its Phase 2 study of ISIS-APOCIII(Rx) in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIII(Rx) achieved average reductions of up to 71 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides, and...

2014-03-31 12:07:41

In an analysis of almost 11,000 patients, an assessment of equations that help guide whether a patient should begin taking a statin (cholesterol lowering medication) found that observed and predicted 5-year atherosclerotic cardiovascular disease risks were similar, suggesting that these equations are helpful for clinical decision making, according to a JAMA study released online to coincide with presentation at the 2014 American College of Cardiology Scientific Sessions. The American...

2014-03-30 08:20:05

Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday THOUSAND OAKS, Calif., March 30, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from two Phase 3 pivotal studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant...

2014-03-29 16:20:11

Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C)...

Winter's Cold May Lead To Higher Cholesterol Levels: Study
2014-03-28 12:02:26

Brett Smith for redOrbit.com - Your Universe Online Past research has shown that heart attacks and heart-related deaths rise during the winter months and researchers at Johns Hopkins Ciccarone Center for the Prevention of Heart Disease recently found that increased cholesterol levels may be to blame. The new study, which is being presented at the American College of Cardiology's 63rd Annual Scientific Session in Washington, DC this week, is based on cholesterol parameters among a sample...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related